Ann: Follow-up Analysis from PREVAIL Phase 2 Study of BNC210 in S, page-10

They will burn half the cash and the rest will be paid out in ridiculous salaries and bonuses.

For those of a charting orientation, the stock is already in overbought territory / but the muppets and naive will probably chase it a bit more before the execs start selling into the strength.

And I’d check your numbers, as I’d be surprised if half the valuation is cash - but just because it is, does not imply that the IP is of equivalent value - because until it passes Phase III clinical trials AND is approved by FDA, it’s basically not worth a razoo!

DDD